NASDAQ:COLL Stock Quote
Collegium Pharmaceutical is a biotechnology company that focuses on developing innovative treatments for pain management and related conditions
The company specializes in formulating and bringing to market unique drug delivery systems and therapies that aim to enhance patient outcomes while addressing issues like opioid misuse and dependence. By leveraging advanced technology and scientific research, Collegium strives to provide healthcare professionals and patients with effective and safer alternatives for managing acute and chronic pain, contributing to improving overall quality of life.
Frequently Asked Questions
Does Collegium Pharmaceutical have any partnerships or collaborations?
Yes, Collegium Pharmaceutical engages in strategic partnerships and collaborations with various organizations, including academic institutions and other pharmaceutical companies. These collaborations enhance its research capabilities and accelerate the development of innovative treatments in pain management.
How can investors get involved with Collegium Pharmaceutical?
Investors interested in Collegium Pharmaceutical can get involved by purchasing shares of the company's stock through a brokerage account. Investors should also stay informed about the company's financial performance, product developments, and industry trends through official reports and investor relations communications.
How does Collegium approach patient education?
Collegium Pharmaceutical approaches patient education through collaboration with healthcare providers and the development of educational materials. The company aims to empower patients with knowledge about pain management options and the responsible use of medications to enhance adherence and improve outcomes.
How does Collegium ensure drug safety and efficacy?
Collegium Pharmaceutical ensures drug safety and efficacy through rigorous clinical trials and compliance with FDA regulations. The company conducts extensive studies to evaluate the safety profile and therapeutic benefits of its products before commercialization, contributing to sound scientific validation of its therapies.
How does Xtampza ER differ from traditional opioid medications?
Xtampza ER is designed with an abuse-deterrent formulation, which makes it difficult to manipulate for non-medical use compared to traditional opioid medications. This mechanism aims to reduce the potential for misuse and supports safer pain management strategies for patients in need of long-term opioid therapy.
Is Collegium involved in any corporate social responsibility initiatives?
Yes, Collegium Pharmaceutical is involved in corporate social responsibility initiatives aimed at raising awareness about responsible pain management and opioid use. The company participates in community outreach programs and partnerships to educate stakeholders on the importance of safe prescribing practices and pain relief options.
Is Collegium Pharmaceutical a publicly traded company?
Yes, Collegium Pharmaceutical is a publicly traded company listed on the Nasdaq stock exchange under the ticker symbol COLL. The company began trading publicly in 2016, providing investors with an opportunity to participate in its growth and success.
What are the financial performance indicators for Collegium Pharmaceutical?
Collegium Pharmaceutical's financial performance is typically measured through various indicators such as revenue growth, profitability, market share, and stock performance. The company reports these metrics quarterly, reflecting its operational efficiency and the commercial success of its product offerings.
What are the future growth prospects for Collegium?
Collegium Pharmaceutical's future growth prospects depend on its ability to expand its product pipeline, successfully bring new therapies to market, and navigate the competitive landscape. The company is focused on leveraging its expertise in pain management to identify new opportunities and continuously improve patient care.
What challenges does Collegium Pharmaceutical face?
Collegium Pharmaceutical faces several challenges, including regulatory hurdles related to opioid medications, competition from other pharmaceutical companies, and the ongoing stigma associated with opioid use. Navigating the changing landscape of healthcare policies and maintaining patient access to necessary medications are critical areas of focus for the company.
What does Collegium Pharmaceutical, Inc. do?
Collegium Pharmaceutical, Inc. is a pharmaceutical company focused on developing and commercializing innovative medicines, particularly for the management of pain and related conditions. The company aims to provide healthcare professionals and patients with effective solutions to address unmet medical needs in pain management.
What is Collegium's approach to addressing the opioid crisis?
Collegium Pharmaceutical addresses the opioid crisis by focusing on the development of abuse-deterrent formulations and providing healthcare providers with education on responsible prescribing practices. Its products aim to balance effective pain management with the need for safety and reduced potential for misuse.
What is the main product of Collegium Pharmaceutical?
Collegium Pharmaceutical's main product is Xtampza ER (oxycodone extended-release), which is an abuse-deterrent formulation of oxycodone designed to manage pain in patients requiring around-the-clock opioid therapy. The product helps mitigate the potential for misuse and abuse typically associated with opioid medications.
What is the mission of Collegium Pharmaceutical?
Collegium Pharmaceutical's mission is to deliver innovative therapies that meet the needs of patients suffering from pain. The company is committed to developing drugs that not only effectively manage pain but also prioritize patient safety and minimize the risks associated with opioid therapy.
What is the target market for Collegium's products?
Collegium Pharmaceutical primarily targets the market of patients with chronic pain requiring opioid therapy, as well as healthcare providers who manage such conditions. The company positions its products to meet the needs of patients while addressing the concerns surrounding opioid prescribing.
What research and development efforts does Collegium focus on?
Collegium Pharmaceutical focuses its research and development efforts on creating novel formulations and delivery systems for pain management medications. This includes exploring products that enhance patient adherence, minimize abuse risks, and improve overall treatment outcomes for patients with chronic pain conditions.
When was Collegium Pharmaceutical founded?
Collegium Pharmaceutical was founded in 2008, and it has since focused on developing innovative treatment options in the pain management sector. The company has grown and adapted to the evolving landscape of healthcare, particularly in response to challenges related to opioid use and regulation.
Where is Collegium Pharmaceutical headquartered?
Collegium Pharmaceutical is headquartered in Stoughton, Massachusetts. This location serves as a central hub for the company's operations, including research and development, regulatory affairs, and commercial activities.
What is the current price of Collegium Pharmaceutical, Inc. - Common Stock?
The current price of Collegium Pharmaceutical, Inc. - Common Stock is 29.36
When was Collegium Pharmaceutical, Inc. - Common Stock last traded?
The last trade of Collegium Pharmaceutical, Inc. - Common Stock was at 2:00 pm EDT on April 2nd, 2025
What is the market capitalization of Collegium Pharmaceutical, Inc. - Common Stock?
The market capitalization of Collegium Pharmaceutical, Inc. - Common Stock is 946.87M
How many shares of Collegium Pharmaceutical, Inc. - Common Stock are outstanding?
Collegium Pharmaceutical, Inc. - Common Stock has 32.25M shares outstanding.